We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne

Simply Wall StMay 8 08:47 ET

Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline

TipRanksMay 8 06:27 ET

Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)

TipRanksMay 8 00:50 ET

Oric Pharmaceuticals Is Maintained at Buy by Citigroup

Oric Pharmaceuticals Is Maintained at Buy by Citigroup

Dow JonesMay 7 13:47 ET

Express News | Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $14

BenzingaMay 7 13:37 ET

ORIC Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 42.99% Citigroup $15 → $14 Maintains Buy 03/27/2024 83.85% JP Morgan $19 → $18 Maintains Overwe

BenzingaMay 7 13:36 ET